OP 69. Investigation of Novel Biomarkers in an Experimental Model of Chronic Heart Failure
E. Végh, B. Sax, K. Nagy, A Kosztin, V. Kékesi, G. Szucs, E. Zima, B. Merkely
Chair(s): Roland Demaria, Mustafa Cikirikcioglu & Violetta Kékesi
8:30 - 8:30h
at Buda Room (B)
Categories: Cardiac and Vascular Surgery, Oral Session
Session: Oral Session VIII - Cardiac and Vascular Surgery II
Background
Pathophysiology of heart failure are under extensive research. Recently, several regulatory peptides, including adrenomedullin (ADM), ghrelin (GHR) and leptin (LT) were suggested to be potential biomarkers of heart failure. We aimed to investigate plasma concentrations of the above peptides in comparison with elevation of the marker endothelin-1 (ET-1) and atrial natriuretic peptide prohormone (proANP), during development of experimental heart failure.
Material and Methods
Pacemaker was implanted in dogs (n=9) for rapid right ventricular pacing (240/min). Echocardiographic measurements were performed weekly, functional staging was assessed, and plasma concentrations of ADM, GHR, LT, ET-1 and proANP (ELISA) were measured simultaneously.
Result
Decompensation of heart failure occured after 22±4 days of pacing. Echocardiography revealed seriously impaired left ventricular function (EF, p<0.01), dilation of left (LVEDD, p<0.01) and right (RVEDD, p<0.01) ventricle, and increasing mitral and tricuspidal insufficiency. Plasma levels of peptides significantly increased (ADM: 440±53 vs 292±48pg/ml; GHR: 1655±286 vs 952±139 pg/ml; LT: 750±241 vs 434±177 pg/ml; ET-1: 5.27±0.94 vs 3.68±0.56 pg/ml; and proANP: 7329±950 vs 870±189ng/ml, p<0.05). Positive correlation was found between GHR level and LVEDD (r=0.44, p<0.05) and LVEDS (r=0.45, p<0.05) parameters, as well as between ET-1 concentration and LVEDS (r=0.48, p<0.02).
Conclusion
Right ventricular tachypacing induced chronic heart failure is suitable for examination of biomarker agents. Significant elevation of plasma adrenomedullin, ghrelin and leptin concentrations during the development of heart failure suggest the possible use of these peptides
as novel biomarkers of the disease.
